Bowel ulceration following tocilizumab administration in a COVID-19 patient

Bowel ulceration following tocilizumab administration in a COVID-19 patient

Tocilizumab, a monoclonal antibody against interleukin-6, has been used to treat cytokine release syndrome (CRS) in a subset of patients with severe COVID-19 disease. Acute ulcerative bowel disease has been only rarely documented in patients treated for rheumatological conditions. The gastrointestin...

Full description

Saved in:
Bibliographic Details
Main Authors: Damian Bruce-Hickman, Shanaz Matthew Sajeed, Yin Huei Pang, Choon Sheong Seow, Weihao Chen, Monika Gulati Kansal
Format: Article
Language:English
Published: BMJ Publishing Group 2020-12-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/7/1/e000484.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items